Ranbaxy Labs awaits FDA re-inspection

Ranbaxy Laboratories said FDA may start inspection of its Dewas, India, plant "any time now," moving the Indian company closer to resuming exports to the world's largest pharmaceutical market from the facility. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.